Alterations of the CDK4/6 signaling pathway is observed in different types of melanoma, concomitantly with NRAS, KRAS or BRAF; thus the genetic profiling of CDK4/6 may provide insights for the targeted treatment of various types of melanoma. The gene discussed is NRAS; the disease is melanoma.